R.J. Zuckerberg Cancer Center
Welcome,         Profile    Billing    Logout  
 10 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bardia, Aditya
TROPION-Breast03, NCT05629585 / 2022-002680-30: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy

Recruiting
3
1075
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Pembrolizumab, KEYTRUDA®
AstraZeneca, Daiichi Sankyo, SWOG Clinical Trials Partnerships
Breast Cancer
09/27
03/30
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
FOENIX-MBC2 TAS-120-201, NCT04024436: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Active, not recruiting
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
07/24
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
HER2-Signal, NCT04901299: Fulvestrant + Neratinib In Breast Cancer

Withdrawn
2
25
US
NERATINIB, Nerlynx, FULVESTRANT, Faslodex
Massachusetts General Hospital, Celcuity, Inc., Puma Biotechnology, Inc.
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
07/24
07/25
LEADER, NCT03285412: CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

Checkmark Presentation of data from LEADER trial for ER+/HER2- breast cancer at SABCS 2022
Oct 2022 - Oct 2022: Presentation of data from LEADER trial for ER+/HER2- breast cancer at SABCS 2022
Recruiting
2
120
US
Ribociclib, Kisqali, Endocrine therapy
Massachusetts General Hospital, Novartis
Breast Cancer
10/24
10/26
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
NeoSTAR, NCT04230109: Sacituzumab Govitecan In TNBC

Recruiting
2
260
US
Sacituzumab Govitecan, IMMU-132, Pembrolizumab
Massachusetts General Hospital, Gilead Sciences
Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
10/25
10/26
NCT04039230: Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Recruiting
1/2
75
US
Talazoparib, Sacituzumab Govitecan
Massachusetts General Hospital, Pfizer
Breast Cancer
12/25
12/26
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
US
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
TAKTIC, NCT03959891: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer

Active, not recruiting
1
77
US
Ipatasertib, GDC-0068, Fulvestrant, Falsodex, Aromatase Inhibitor, Letrozole, Palbociclib, Ibrance
Massachusetts General Hospital, Genentech, Inc.
Breast Cancer
12/22
12/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Raptis, George
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Melina Study, NCT05178004: Microbiome and Immune Profiling in Infant With Cow's Milk Allergy

Recruiting
N/A
150
Europe
Faecal and Urine sample collection
University of Glasgow, NHS Greater Glasgow and Clyde Board HQ, Nutricia, Inc.
Cow Milk Allergy
12/22
12/22
Wander, Seth
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
ELAINEIII, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
400
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
06/25
06/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05608252: VS-6766+Abema+Fulv in Met HR+/HER- BC

Recruiting
1/2
63
US
VS-6766, Abemaciclib, Verzenio, Fulvestrant, Faslodex
Adrienne G. Waks, Verastem, Inc., Eli Lilly and Company
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
12/27
12/28
TAKTIC, NCT03959891: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer

Active, not recruiting
1
77
US
Ipatasertib, GDC-0068, Fulvestrant, Falsodex, Aromatase Inhibitor, Letrozole, Palbociclib, Ibrance
Massachusetts General Hospital, Genentech, Inc.
Breast Cancer
12/22
12/24

Download Options